Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 17/20 | 0.55 |
| ▸ | MET | P08581 | 5/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.52 |
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | KIT | P10721 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574003 | 1.00 | CSF1R (0.55) | CSF1RMETKDRAXLPDGFRB | |
| SCHEMBL574217 | 0.99 | AXL (0.55) | CSF1RMETKDRAXLPDGFRB | |
| SCHEMBL573622 | 0.88 | CSF1R (0.56) | CSF1RMETKDRAXLPDGFRB | |
| SCHEMBL572506 | 0.87 | AXL (0.51) | CSF1RMETKDRAXLPDGFRB | |
| SCHEMBL574041 | 0.87 | CSF1R (0.57) | CSF1RMETKDRAXLPDGFRB | |
| SCHEMBL828021 | 0.85 | CSF1R (0.54) | CSF1RMETKDRAXLPDGFRB | |
| SCHEMBL574152 | 0.85 | CSF1R (0.54) | CSF1RMETKDRAXLPDGFRB | |
| SCHEMBL3665924 | 0.84 | AXL (0.61) | CSF1RMETKDRAXLPDGFRB | |
| SCHEMBL573252 | 0.84 | CSF1R (0.54) | CSF1RMETKDRAXLPDGFRB | |
| SCHEMBL573950 | 0.84 | AXL (0.51) | CSF1RMETKDRAXLPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | CSF1R 197/4885MET 168/4885KDR 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.